In the last trading session, 1.08 million ARS Pharmaceuticals Inc (NASDAQ:SPRY) shares changed hands as the company’s beta touched 0.88. With the company’s per share price at $13.61 changed hands at $0.29 or 2.18% during last session, the market valuation stood at $1.32B. SPRY’s last price was a discount, traded about -36.0% off its 52-week high of $18.51. The share price had its 52-week low at $4.94, which suggests the last value was 63.7% up since then. When we look at ARS Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.94 million shares, with the 3-month average coming to 1.06 million.

Analysts gave the ARS Pharmaceuticals Inc (SPRY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SPRY as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. ARS Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.0.

ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information

Instantly SPRY was in green as seen at the end of in last trading. With action -0.73%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 148.36%, with the 5-day performance at -0.73% in the red. However, in the 30-day time frame, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is -10.81% down. Looking at the short shares, we see there were 13.85 million shares sold at short interest cover period of 10.98 days.

The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 38.14% from its current market value. According to analyst projections, SPRY’s forecast low is 18 with 30 as the target high. To hit the forecast high, the stock’s price needs a -120.43% plunge from its current level, while the stock would need to soar -32.26% for it to hit the projected low.

ARS Pharmaceuticals Inc (SPRY) estimates and forecasts

Data shows that the ARS Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 52.24% over the past 6 months, a 12.28% in annual growth rate that is considerably lower than the industry average of 16.60%. Year-over-year growth is forecast to reach 93,770.00% up from the last financial year.

Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 25.58M. 3 analysts are of the opinion that ARS Pharmaceuticals Inc’s revenue for the current quarter will be 10.36M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -1.44%. The 2024 estimates are for ARS Pharmaceuticals Inc earnings to increase by 12.72%.

SPRY Dividends

ARS Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.

ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 23.30% of ARS Pharmaceuticals Inc shares while 68.11% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.80%. There are 68.11% institutions holding the ARS Pharmaceuticals Inc stock share, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) the top institutional holder. As of 2024-06-30, the company held 11.4409% of the shares, roughly 11.08 million SPRY shares worth $94.27 million.

RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 11.2168% or 10.86 million shares worth $92.43 million as of 2024-06-30.